BMS' Capoten for diabetic nephropathy
Executive Summary
The ACE inhibitor is "approvable" as of Jan. 10 for the treatment of diabetic nephropathy in patients with Type I insulin- dependent diabetes and retinopathy. FDA's Cardiovascular & Renal Drugs Advisory Committee recommended the supplemental use on Oct. 28, 1993...